Prima Biomed Ltd.'s quest to divest its one-time lead program, Cvac, has ended with the cell therapy's adoption by biotech entrepreneur Joseph Hernandez, who will carry it ahead under the banner of Sydys Corp., a repurposed public company that will seek to fund new trials to build on earlier data in ovarian cancer. The deal includes more than A$400 million (US$293 million) in potential development, regulatory and commercial milestone payments, but no up-front cash.